Mekonos is a bio-technology company which has developed Iris™, an innovative system-on-a-chip platform that enables effective delivery of drug payload(s) to individual cells through thousands of nano-needles. This high-tech methodology has a substantially higher delivery conversion rate than more traditional virus-based cell editing methods. 

Now based in Silicon Valley, the novel micro-electromechanical system (MEMS) technology originated from a PhD research project at the University of Canterbury, and was further developed at Stanford University, the University of California Berkeley, and Novartis Research Labs. Combined with novel gene and cell therapy drugs, Mekonos can improve the treatment of diseases with a genetic element, including cancers, at massive scale and a significantly reduced cost. 

Growing their technology, IP, and customer base, Mekonos closed a USD$25 million Series A capital raise in 2021, enabling the signing of several high promise disruptive technological partnerships across a range of bio-tech industries. Matū continues to support Mekonos in their executive and strategic capabilities.